Use este identificador para citar ou linkar para este item: https://locus.ufv.br//handle/123456789/22894
Tipo: Artigo
Título: Antimetastatic effect of the pharmacological inhibition of serine/arginine-rich protein kinases (SRPK) in murine melanoma
Autor(es): Moreira, Gabriela Alves
Lima, Graziela Domingues de Almeida
Siqueira, Raoni Pais
Barros, Marcus Vinícius de Andrade
Adjanohoun, Abraham Landry Mahuvi
Santos, Viviane Corrêa
Barbosa, Éverton de Almeida Alves
Loterio, Robson Kriiger
Paiva, Janine Cerqueira de
Gonçalves, Victor Hugo Sousa
Viol, Lívia Cristina de Souza
Marques-da-Silva, Eduardo de Almeida
Silva Júnior, Abelardo
Almeida, Márcia Rogéria
Fietto, Juliana Lopes Rangel
Machado-Neves, Mariana
Ferreira, Rafaela Salgado
et al.
Abstract: The Serine/arginine-rich protein kinases (SRPK) are involved in pre-mRNA splicing control through the phosphorylation of the SR protein family of splicing factors. Over the last years, several studies have shown the relevance of SRPK for human cancers and their potential as promising drug targets. In this context, we have previously selected three trifluoromethyl arylamides (named here as SRVIC24, SRVIC30 and SRVIC36) with improved in vitro antileukemia effect and ability of impairing the cellular activity of SRPK. Given the increasing amount of reports on the implication of these kinases in metastatic cancers, in this study, we have evaluated the antimetastatic effect of these compounds and the known SRPK inhibitor (SRPIN340) on a murine model of metastatic melanoma. The compounds were able to impact the melanoma cell metastatic behavior by decreasing migration, invasion, adhesion, and colony formation in in vitro assays. Also, they presented antimetastatic in vivo activity, without apparent signs of systemic toxicity after treatments, as revealed by the histology of organs and analysis of key serum biochemical markers. Moreover, the effect of the treatments on SRPK1 nuclear translocation and SR protein phosphorylation was observed. Finally, molecular docking studies were carried out to gain structural information on the SRPK-compound complexes. Together, these data suggest that SRPK pharmacological inhibition should be considered as an interesting therapeutic strategy against metastatic cancers.
Palavras-chave: Serine/Arginine-rich
Protein kinases
Metastasis
Melanoma
SRVIC compounds
Editor: Toxicology and Applied Pharmacology
Tipo de Acesso: 2018 Elsevier Inc. All rights reserved.
URI: https://doi.org/10.1016/j.taap.2018.08.012
http://www.locus.ufv.br/handle/123456789/22894
Data do documento: 1-Out-2018
Aparece nas coleções:Artigos

Arquivos associados a este item:
Arquivo Descrição TamanhoFormato 
artigo.pdf
  Until 2100-12-31
Texto completo2,74 MBAdobe PDFVisualizar/Abrir ACESSO RESTRITO


Os itens no repositório estão protegidos por copyright, com todos os direitos reservados, salvo quando é indicado o contrário.